Psoriatic Arthritis
Recap
Treating Active Psoriatic Arthritis When the First-Line Biologic Fails
The complex question of how to treat active psoriatic arthritis after the first biologic therapy fails is addressed by Dr Atul Deodar, who draws...
Latest News
LITE Study Provides Encouraging Data on Home-Based Phototherapy for Psoriasis
Office-based phototherapy is not available in 90% of counties in the United States, “and a lack of US data has resulted in many insurance...
From the Journals
Early Diagnosis Improves Clinical Outcomes in Psoriatic Arthritis
Psoriatic arthritis diagnosis by a rheumatologist within a year of symptom onset improved long-term clinical outcomes, a study showed.
Latest News
Sustained Control Reported for Anti–IL-17, Anti–IL-23 Psoriasis Treatments
Longer follow up is with the IL-17 inhibitor bimekizumab. In a 4-year open-label extension study, the PASI 90 rate was approximately 85% in...
Conference Coverage
AI’s Future and Current Role in Rheumatology
Today’s constantly evolving and growing applications of AI to the practice of medicine bring opportunities for rheumatologists to improve workflow...
Conference Coverage
Leflunomide: A Fresh Look at an Old Drug
Overlooked in the biologic era, it still has a place.
From the Journals
How Good are Tools to Screen for Spondyloarthritis in Patients With Psoriasis, Uveitis, IBD?
A comparison of screening tools for SpA in conditions that commonly co-occur with the disease revealed few screening tool options for patients...
Latest News
Study Evaluates Factors Driving Fatigue in Patients With Psoriasis, PsA
The study “highlights the importance of a symptom-based approach when treating psoriasis, ” the authors wrote.
News from the FDA/CDC
FDA Approves 10th Humira Biosimilar, With Interchangeability
Adalimumab-ryvk (Simlandi) is the first adalimumab biosimilar in a high-concentration formulation to receive interchangeability status from the...
From the Journals
Ixekizumab’s Final Safety Results Reported Across 25 Trials in Psoriasis, PsA, Axial SpA
Final safety results from 25 randomized clinical trials were consistent with previous reports at up to 6 years’ follow-up.
Latest News
Use of Biologics for Psoriasis Found to Confer a Survival Benefit
The study population consisted of 18,618 psoriasis cases and 55,854 controls.